Given the essential role of Smad2/3 signaling in TRIM9-induced tumor progression, it should be feasible to suppress Smad2/3 molecule to improve the outcome of chemotherapy in TRIM9-high patients. The gene discussed is SMAD2; the disease is neoplasm.